BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

234 related articles for article (PubMed ID: 15080792)

  • 1. The ErbB2/Neu/HER2 receptor is a new calmodulin-binding protein.
    Li H; Sánchez-Torres J; Del Carpio A; Salas V; Villalobo A
    Biochem J; 2004 Jul; 381(Pt 1):257-66. PubMed ID: 15080792
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Epidermal growth factor receptor coexpression modulates susceptibility to Herceptin in HER2/neu overexpressing breast cancer cells via specific erbB-receptor interaction and activation.
    Diermeier S; Horváth G; Knuechel-Clarke R; Hofstaedter F; Szöllosi J; Brockhoff G
    Exp Cell Res; 2005 Apr; 304(2):604-19. PubMed ID: 15748904
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The adaptor Grb7 is a novel calmodulin-binding protein: functional implications of the interaction of calmodulin with Grb7.
    Li H; Sánchez-Torres J; del Carpio AF; Nogales-González A; Molina-Ortiz P; Moreno MJ; Török K; Villalobo A
    Oncogene; 2005 Jun; 24(26):4206-19. PubMed ID: 15806159
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Epidermal growth factor receptor (HER1) tyrosine kinase inhibitor ZD1839 (Iressa) inhibits HER2/neu (erbB2)-overexpressing breast cancer cells in vitro and in vivo.
    Moulder SL; Yakes FM; Muthuswamy SK; Bianco R; Simpson JF; Arteaga CL
    Cancer Res; 2001 Dec; 61(24):8887-95. PubMed ID: 11751413
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The efficacy of ErbB receptor-targeted anticancer therapeutics is influenced by the availability of epidermal growth factor-related peptides.
    Motoyama AB; Hynes NE; Lane HA
    Cancer Res; 2002 Jun; 62(11):3151-8. PubMed ID: 12036928
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Epidermal growth factor and betacellulin mediate signal transduction through co-expressed ErbB2 and ErbB3 receptors.
    Alimandi M; Wang LM; Bottaro D; Lee CC; Kuo A; Frankel M; Fedi P; Tang C; Lippman M; Pierce JH
    EMBO J; 1997 Sep; 16(18):5608-17. PubMed ID: 9312020
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Houttuyninum, an active constituent of Chinese herbal medicine, inhibits phosphorylation of HER2/neu receptor tyrosine kinase and the tumor growth of HER2/neu-overexpressing cancer cells.
    Zhou NN; Tang J; Chen WD; Feng GK; Xie BF; Liu ZC; Yang D; Zhu XF
    Life Sci; 2012 May; 90(19-20):770-5. PubMed ID: 22525372
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Epidermal growth factor receptor, c-erbB2 and c-erbB3 receptor interaction, and related cell cycle kinetics of SK-BR-3 and BT474 breast carcinoma cells.
    Brockhoff G; Heiss P; Schlegel J; Hofstaedter F; Knuechel R
    Cytometry; 2001 Aug; 44(4):338-48. PubMed ID: 11500850
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Constitutive activation of the neuregulin-1/ErbB receptor signaling pathway is essential for the proliferation of a neoplastic Schwann cell line.
    Frohnert PW; Stonecypher MS; Carroll SL
    Glia; 2003 Aug; 43(2):104-18. PubMed ID: 12838503
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Resistance to small molecule inhibitors of epidermal growth factor receptor in malignant gliomas.
    Li B; Chang CM; Yuan M; McKenna WG; Shu HK
    Cancer Res; 2003 Nov; 63(21):7443-50. PubMed ID: 14612544
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Truncated ErbB2 receptor (p95ErbB2) is regulated by heregulin through heterodimer formation with ErbB3 yet remains sensitive to the dual EGFR/ErbB2 kinase inhibitor GW572016.
    Xia W; Liu LH; Ho P; Spector NL
    Oncogene; 2004 Jan; 23(3):646-53. PubMed ID: 14737100
    [TBL] [Abstract][Full Text] [Related]  

  • 12. AEE788: a dual family epidermal growth factor receptor/ErbB2 and vascular endothelial growth factor receptor tyrosine kinase inhibitor with antitumor and antiangiogenic activity.
    Traxler P; Allegrini PR; Brandt R; Brueggen J; Cozens R; Fabbro D; Grosios K; Lane HA; McSheehy P; Mestan J; Meyer T; Tang C; Wartmann M; Wood J; Caravatti G
    Cancer Res; 2004 Jul; 64(14):4931-41. PubMed ID: 15256466
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A novel mechanism for integrin-mediated ras activation in breast carcinoma cells: the alpha6beta4 integrin regulates ErbB2 translation and transactivates epidermal growth factor receptor/ErbB2 signaling.
    Yoon SO; Shin S; Lipscomb EA
    Cancer Res; 2006 Mar; 66(5):2732-9. PubMed ID: 16510594
    [TBL] [Abstract][Full Text] [Related]  

  • 14. ErbB2/neu kinase modulates cellular p27(Kip1) and cyclin D1 through multiple signaling pathways.
    Lenferink AE; Busse D; Flanagan WM; Yakes FM; Arteaga CL
    Cancer Res; 2001 Sep; 61(17):6583-91. PubMed ID: 11522658
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ca2+/Calmodulin and Apo-Calmodulin Both Bind to and Enhance the Tyrosine Kinase Activity of c-Src.
    Stateva SR; Salas V; Anguita E; Benaim G; Villalobo A
    PLoS One; 2015; 10(6):e0128783. PubMed ID: 26058065
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Anti-tumor activity of GW572016: a dual tyrosine kinase inhibitor blocks EGF activation of EGFR/erbB2 and downstream Erk1/2 and AKT pathways.
    Xia W; Mullin RJ; Keith BR; Liu LH; Ma H; Rusnak DW; Owens G; Alligood KJ; Spector NL
    Oncogene; 2002 Sep; 21(41):6255-63. PubMed ID: 12214266
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prolactin modulates phosphorylation, signaling and trafficking of epidermal growth factor receptor in human T47D breast cancer cells.
    Huang Y; Li X; Jiang J; Frank SJ
    Oncogene; 2006 Dec; 25(58):7565-76. PubMed ID: 16785991
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Molecular analysis of the erbB gene family calmodulin-binding and calmodulin-like domains in astrocytic gliomas.
    Arjona D; Bello MJ; Alonso ME; Gonzalez-Gomez P; Lomas J; Aminoso C; Lopez-Marin I; Isla A; De Campos JM; Vaquero J; Gutierrez M; Villalobo A; Rey JA
    Int J Oncol; 2004 Nov; 25(5):1489-94. PubMed ID: 15492843
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A naturally occurring secreted human ErbB3 receptor isoform inhibits heregulin-stimulated activation of ErbB2, ErbB3, and ErbB4.
    Lee H; Akita RW; Sliwkowski MX; Maihle NJ
    Cancer Res; 2001 Jun; 61(11):4467-73. PubMed ID: 11389077
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Peptide aptamers with binding specificity for the intracellular domain of the ErbB2 receptor interfere with AKT signaling and sensitize breast cancer cells to Taxol.
    Kunz C; Borghouts C; Buerger C; Groner B
    Mol Cancer Res; 2006 Dec; 4(12):983-98. PubMed ID: 17189388
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.